Nabuflex 750mg Tablet

Nabuflex 500 mg is prescribed for the symptomatic management of osteoarthritis and rheumatoid arthritis. Before initiating therapy, the expected therapeutic benefits should be carefully weighed against potential risks. Treatment should always be initiated at the lowest effective dose and continued for the shortest duration necessary to achieve individual patient goals.

Nabuflex 500 mg (nabumetone) is a naphthylalkanone non-steroidal anti-inflammatory drug (NSAID). It acts as a non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, thereby suppressing prostaglandin synthesis. Prostaglandins play a key role in mediating inflammation, pain, fever, and platelet aggregation.

Nabuflex is administered as a prodrug, which undergoes hepatic metabolism to its active form, 6-methoxy-2-naphthylacetic acid (6-MNA). This metabolite is a potent inhibitor of prostaglandin synthesis and is primarily responsible for the drug’s analgesic, anti-inflammatory, and antipyretic effects.

Following hepatic conversion to 6-MNA, Nabuflex inhibits COX-1 and COX-2 enzymes, leading to reduced formation of prostaglandins involved in pain, inflammation, and fever. This mechanism underlies its therapeutic action in inflammatory joint disorders.

Dosage & Administration

Osteoarthritis and Rheumatoid Arthritis (Adults):

Initial recommended dose: 1000 mg once daily, with or without food

Depending on clinical response, the dose may be increased to 1500–2000 mg per day, given as a single dose or divided into two doses

Doses exceeding 2000 mg/day have not been adequately studied

Use the lowest effective dose for long-term therapy

Patients weighing <50 kg:

Often respond adequately to 1000 mg/day

Dose adjustment should be based on individual response

Renal Impairment:

Moderate renal insufficiency: Maximum starting dose 750 mg once daily

Severe renal insufficiency: Maximum starting dose 500 mg once daily

With careful monitoring, daily doses may be increased up to 1500 mg and 1000 mg, respectively

Pediatric Use:

Safety and efficacy in children have not been established

Drug Interactions

Concomitant use with ACE inhibitors may reduce the antihypertensive effect of these agents

Caution is advised when Nabuflex is used alongside other NSAIDs or nephrotoxic agents

Contraindications

Nabuflex 500 mg is contraindicated in patients with:

Known hypersensitivity to nabumetone or any formulation component

History of asthma, urticaria, or allergic reactions following aspirin or other NSAIDs

Use for peri-operative pain in coronary artery bypass graft (CABG) surgery

Side Effects

Gastrointestinal:
Diarrhea, dyspepsia, abdominal discomfort, constipation, flatulence, nausea, vomiting, gastritis, stomatitis, dry mouth, and positive fecal occult blood

Central Nervous System:
Headache, dizziness, fatigue, somnolence, insomnia, nervousness, increased sweating

Dermatologic:
Rash, pruritus

Special Senses:
Tinnitus

Miscellaneous:
Peripheral edema

Pregnancy & Lactation

Pregnancy:

Category C

Animal studies have not demonstrated teratogenic effects, but adequate human studies are lacking

Use during pregnancy only if the potential benefit outweighs the potential risk

Use during the third trimester is not recommended due to the risk of premature closure of the ductus arteriosus

Lactation:

Nabuflex is not recommended during breastfeeding due to the potential risk of adverse effects in nursing infants

Precautions & Warnings

Long-term NSAID use may cause renal toxicity, including renal papillary necrosis

Patients at increased risk include those with renal impairment, heart failure, liver dysfunction, dehydration, diuretic use, and the elderly

Renal function should be monitored during prolonged therapy

Discontinuation of the drug generally leads to recovery of renal function

Overdose

Symptoms of overdose may include lethargy, drowsiness, nausea, vomiting, epigastric pain, and gastrointestinal bleeding. Rarely, severe effects such as hypertension, acute renal failure, respiratory depression, or coma may occur.

Management consists of supportive and symptomatic care. Activated charcoal may be considered if ingestion occurred within 4 hours. There is no specific antidote. Hemodialysis is generally ineffective due to high protein binding. Overdoses of up to 25 g have been reported without long-term adverse outcomes following appropriate emergency treatment.

Storage Conditions

Store in a cool, dry place, protected from light and moisture.
Keep out of the reach of children.

Use in Special Populations

Pediatric patients: Not established

Geriatric patients: Use with caution due to increased risk of renal and gastrointestinal adverse effects